FIELD: immunology.
SUBSTANCE: present invention relates to immunology, in particular to a method for the treatment of cancer characterized by Trop-2 expression. The method includes the injection to a subject of an antibody-drug conjugate SN-38 (irinotecan) in a combination with Rad51 inhibitor. The specified conjugate is known as IMMU-132 (satsituzumab govitecan). B02 or RI-1 can be used as Rad51 inhibitor. The specified combination of the conjugate and Rad51 inhibitor can reduce the size of solid tumors, reduce or eliminate metastases and is effective for the treatment of cancer diseases resistant to standard treatment methods, such as radiation therapy, chemotherapy or immunotherapy.
EFFECT: present invention allows improving the efficiency of methods for the therapy of a cancer expressing Trop-2.
26 cl, 36 dwg, 5 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPY OF METASTATIC UROTHELIAL CANCER USING ANTIBODY-DRUG CONJUGATE SATSITUZUMAB GOVITECAN (IMMU-132) | 2017 |
|
RU2757395C2 |
| EFFICACY OF CONJUGATES OF ANTI-TROP-2 ANTIBODY WITH DRUG SN-38 FOR THERAPY OF RECURRENT/REFRACTORY TO INHIBITORS OF TUMOR CONTROL POINT | 2017 |
|
RU2725292C2 |
| CONJUGATE OF TROP-2 ANTIBODY AND EXATECAN ANALOGUE AND MEDICAL USE THEREOF | 2021 |
|
RU2830167C1 |
| ANTI-TROP2 ANTIBODY-DRUG CONJUGATE | 2014 |
|
RU2743077C2 |
| ANTI-PD-L1 ANTIBODY AND ITS USE | 2020 |
|
RU2783685C2 |
| ERIBULIN DERIVATIVE DRUG CONJUGATE, METHOD FOR PREPARATION THEREOF AND USE THEREOF IN MEDICINE | 2021 |
|
RU2830242C1 |
| THERAPEUTIC COMBINATIONS CONTAINING ANTI-FOLR1 IMMUNOCONJUGATES | 2016 |
|
RU2749865C2 |
| ANTI-FOLR1 IMMUNOCONJUGATE APPLICATION SCHEMES | 2014 |
|
RU2801307C1 |
| ANTIBODY-DRUG CONJUGATES AND METHODS OF USING SAID CONJUGATES OF PYRROLOBENZODIAZEPINE | 2016 |
|
RU2736725C1 |
| ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF THEIR APPLICATION | 2019 |
|
RU2806049C2 |
